Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 180 nmol/ml; insulin degludec, quantity: 420 nmol/ml - injection, solution - excipient ingredients: zinc acetate; phenol; hydrochloric acid; sodium chloride; metacresol; water for injections; sodium hydroxide; glycerol - for use in diabetes mellitus in patients aged 6 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin degludec, quantity: 420 nmol/ml; insulin aspart, quantity: 180 nmol/ml - injection, solution - excipient ingredients: water for injections; metacresol; phenol; zinc acetate; sodium hydroxide; glycerol; hydrochloric acid; sodium chloride - for use in diabetes mellitus in patients aged 6 years and older.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - insulin aspart(genetical recombination)[insulin aspart biosimilar 1] - clear and colorless injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - insulin aspart(genetical recombination)[insulin aspart biosimilar 1] - clear and colorless injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - insulin aspart(genetical recombination)[insulin aspart biosimilar 1] - clear and colorless injection, (body) dark gray, (injection button) pale orange

Canada - English - Health Canada

novo nordisk canada inc - insulin aspart; insulin aspart protamine - suspension - 30%; 70% - insulin aspart 30%; insulin aspart protamine 70% - insulins

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

biocon sdn bhd - insulin aspart -

Israel - English - Ministry of Health

novo nordisk ltd, israel - insulin aspart - suspension for injection - insulin aspart 100 iu/ml - insulin aspart - insulin aspart - treatment of diabetes mellitus.

Canada - English - Health Canada

novo nordisk canada inc - insulin aspart; insulin aspart protamine - suspension - 30unit; 70unit - insulin aspart 30unit; insulin aspart protamine 70unit - insulins

United States - English - NLM (National Library of Medicine)

novo nordisk pharma, inc. - insulin degludec (unii: 54q18076qb) (insulin degludec - unii:54q18076qb) - insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. limitations of use insulin degludec is contraindicated: risk summary available data from one unpublished trial and the published literature with insulin degludec use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label actively controlled clinical trial that included 91 pregnant women with type 1 diabetes who were administered insulin degludec once daily and insulin aspart, beginning in gestational weeks 8 to 13 or prior to conception, no clear evidence of maternal or fetal risk associated with insulin degludec use was observed (see data ). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin degludec in animal reproduction studies during organogene